The content on this site is intended for healthcare professionals only
Characterisation of novel subtypes in B progenitor acute lymphoblastic leukaemia
Bispecific CD19/22 CAR therapy in children and young adults with ALL
Checkpoint blockade therapy may sensitise non-Hodgkin lymphoma to subsequent therapy
Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smouldering multiple myeloma
Indoximod combined with chemotherapy in newly diagnosed AML patients
Combined ibrutinib and venetoclax in patients with treatment-naïve high-risk CLL
Phase II trial of nivolumab combined with ibrutinib for patients with Richter transformation
CAR-T cell dosing approaches in treating acute lymphoblastic leukaemia
Ibrutinib with obinutuzumab in patients with chronic lymphocytic leukaemia
Results of using dara-CyBorD to treat patients with newly diagnosed or relapsed multiple myeloma
Blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-NHL
Cytotoxic T lymphocyte cell therapy for post-transplant lymphoproliferative disorder in the central nervous system
Results from the EMN-011 trial, combination therapy for multiple myeloma
Maintenance therapy with the oral PI ixazomib significantly prolongs PFS following ASCT in multiple myeloma
Efficacy and safety of KRd or KCd induction in multiple myeloma
Clinical impact of an accurate genetic characterisation of older AML patients
Two clinical trials using combination therapy in adult patients with multiple myeloma
The combined analysis of carfilzomib trials for multiple myeloma
Gilteritinib combined with induction and consolidation chemotherapy in newly diagnosed AML patients
ECHELON-2: Study into brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients with T-Cell lymphomas
Results from RIALTO, blinatumomab for paediatric patients with B-cell precursor relapsed/refractory ALL
Alpha/beta T-cell and B-cell depletion haplo-HSCT is an effective treatment for children with acute leukaemia
Matched targeted therapy for paediatric patients with relapsed, refractory or high-risk leukemias
Axicabtagene Ciloleucel in patients with refractory large B Cell lymphoma
AMG 330: an anti-CD33 bispecific T-Cell engager antibody construct in relapsed/refractory AML
KRd versus VRd in patients with newly diagnosed multiple myeloma
Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL
Daratumumab increases PFS in patients with transplant-ineligible multiple myeloma
Researchers identify mutation that causes resistance to venetoclax in CLL patients
Daratumumab found to increase PFS in patients with transplant-ineligible newly diagnosed multiple myeloma
Ibrutinib-based therapy superior for younger patients with previously untreated CLL compared with current standard of care
Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy
Resistance mechanisms to venetoclax in patients with progressive CLL
Patient treatment preferences in relapsed/refractory multiple myeloma
Landscape change with oral proteasome maintenance in multiple myeloma patients
The importance of NF-kB pathway in myeloma
Multiple myeloma highlights and more from ASH 2018
Results of the Beat AML umbrella study for previously untreated acute myeloid leukaemia
An integrated view of the role of the B cell antigen receptor in lymphoma cell fitness
Myeloma XI study: Quadruplet regimen for transplant eligible patients
Developments in CAR T treatments for adult patients
Outcomes for patients with disease progression following CD19-specific CAR T-cell therapy
ASH 2018: Expert overview of the latest in CLL, ALL and AML
Updates on the ELIANA trial for acute lymphocytic leukaemia in young patients
Determining the prognosis of patients with myelodysplastic syndromes using machine learning
The benefits of a stem cell transplant after CAR T-cell therapy in paediatric patients
Long term data from JULIET trial, using tisagenlecleucel for patients with relapsed or treatment-resistant DLBCL
ACT-1: Addition of alemtuzumab to a CHOP backbone for young patients with T-cell lymphoma
ECHELON-2: a large peripheral T-cell lymphoma trial
Link between gut microbiota and haematopoietic cell transplantation outcomes
Initial report of the Beat AML umbrella study for previously untreated AML
Machine learning algorithm improves prognosis accuracy for patients with myelodysplastic syndromes
Diversity of gut microbiota linked with complications from haematopoietic cell transplantation
Progression-free survival milestones in primary central nervous system lymphoma
Relapse risk and loss in expectation of lifetime in young classical hodgkin lymphoma patients
New therapies for transfusion dependent MDS patients
Reduction of chemotherapy cycles for diffuse large B-cell lymphoma
Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy
Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell therapy for relapsed and/or refractory CLL
Ibrutinib alone and in combination with rituximab for older patients with chronic lymphocytic leukaemia
Stem cell transplant after CAR T-cell therapy reduces relapses in acute lymphocytic leukaemia
CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia
Latest results from JULIET: Tisagenlecleucel in adults with DLBCL
CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute lymphocytic leukaemia
Latest analysis of the ELIANA trial for acute lymphocytic leukaemia
Four cycles of chemotherapy as effective as six for diffuse large B-Cell lymphoma
Results from the MEDALIST trial for patients with anaemia in MDS
Ibrutinib outperforms chemoimmunotherapy in older patients with chronic lymphocytic leukaemia
Luspatercept reduces need for blood transfusions in beta thalassemia and MDS
